Last updated: April 25, 2026
What does JP7574204 cover, and how does it shape the Japan drug patent landscape?
JP7574204 is a Japanese drug patent family entry that is tied to a specific active ingredient and therapeutic use in Japan. Based on the available bibliographic and legal- status material indexed for this publication, the patent’s measurable impact is in (1) claim boundaries around the claimed compositions and/or methods, (2) whether it blocks downstream “same-ingredient/same-salt/same-dosage-form” generics, and (3) whether it creates enforceable distinctions versus earlier filings held by competing originators.
This analysis maps: (a) what the claims are technically likely to protect, (b) where those claims sit relative to adjacent filings in Japan, and (c) the practical “design-around” pressure points that determine whether generic entry can proceed on the basis of non-infringement or regulatory reliance.
What is JP7574204 (publication record) and where does it sit in the family tree?
JP7574204 is a Japanese publication (JP publication number) that corresponds to an “active-ingredient centered” drug patent family. In Japan, this typically means enforcement is framed through product-by-composition and/or method claims that can be used against manufacture, sale, and import of infringement products.
Family structure in Japan typically follows this pattern (for this type of filing):
- Core priority: an international application or national filing in the earliest jurisdiction
- Japan national phase / entry: publication as a JP number
- Branching: divisional applications and continuations where claim scope is narrowed or re-positioned
Landscape placement (functional view):
- JP7574204 is best treated as a claim-boundary upgrade relative to earlier family members, where the later Japan publication often:
- tightens definitions for the active ingredient form (salt/polymorph/solvate)
- tightens dosage regimen
- tightens formulation or device parameters (when applicable)
What is the technical scope of protection likely captured by JP7574204 claims?
Japanese drug patents in this class typically protect one or more of the following categories. JP7574204’s enforceable scope depends on claim language, but the practical field-of-use structure in Japan usually lines up with these “buckets”:
Composition scope
A typical composition claim set in Japan covers one or more of:
- the active ingredient as such (or as a defined chemical entity)
- a defined chemical form (salt, polymorph, solvate, hydrate)
- a defined formulation (excipient composition constraints, particle size, concentration ranges)
- a defined combination (co-administered agents, fixed-dose ratios, sequence of administration in method claims)
Method of treatment scope
Method claims usually constrain:
- the patient population (e.g., disease state, biomarker-positive status)
- the therapeutic indication
- the dosing regimen (mg range, frequency, titration schedule)
- the route of administration (oral, injection, infusion)
- the end point (sometimes tied to a measurable therapeutic response)
Manufacturing scope
In Japan, process claims may exist but are less determinative for generic entry unless manufacturing steps are clearly required and sufficiently narrow.
Key business point: For generics, composition claims create the most straightforward infringement risk when the generic product uses the same active ingredient form and formulation characteristics. Method claims matter when a generic’s label or real-world use falls within the claimed regimen.
How do JP7574204 claims affect generic entry under Japan’s infringement framework?
Japan infringement practice is claim-driven. The practical question for generic strategy is: does the generic product fall within the literal claim language (or under Japanese equivalents doctrine, where applicable).
For a drug patent like JP7574204, the strongest infringement vectors are:
- Same active ingredient identity (same chemical entity)
- Same defined form (same salt/polymorph/solvate if claims require it)
- Same dosage regimen and indication (if method claims are broad and label-aligned)
- Same formulation parameters (if composition claims define excipients or ranges)
Common generics response levers:
- switch to a different salt/polymorph
- use a different dosage form or formulation composition
- change regimen to fall outside the defined dose range or frequency
- alter the label/indication to avoid method-use infringement
If JP7574204’s claims are tightly limited to a very specific salt/form or regimen, generics can sometimes enter earlier by designing around those constraints. If the claims are broad and read on the marketed generic form and label, entry is typically blocked until expiry or a carve-out is negotiated.
What does the Japan patent landscape look like around JP7574204 (blocking vs crowding)?
JP7574204 does not exist alone; it sits inside a web of earlier and later family publications in Japan and sometimes parallel patents from separate applicants (same drug class).
How to read the landscape
In practice, you look for three things:
- Earliest priority cohort: the originator’s first filing set
- Later improvement cohort: salt form, polymorph, formulation, device, and regimen refinements
- Parallel competitor cohort: other applicants’ process or formulation patents that can create additional barriers
Typical landscape patterns for originator families
In Japan, originator families often create layered protection that covers:
- active ingredient (core)
- improvements in form or formulation (secondary)
- improvements in method or combination (tertiary)
The result is a “cliff” effect in freedom-to-operate: even if one claim set expires, another active claim set can still block entry.
Typical landscape patterns for competitors
Competing applicants often try to carve space through:
- distinct salt forms
- different dosage forms
- different dosing schedules
- different combinations or patient subsets
If JP7574204 claims are narrow, the landscape tends to be crowded with carve-out opportunities. If claims are broad, the landscape tends to be “blocking,” where many competitor designs still land inside the same claim boundaries.
What are the most likely claim-content risk points for generic manufacturers?
Without reproducing the full text of JP7574204 claims here, the risk points that consistently drive infringement outcomes in Japan for this patent type are:
- Salt/polymorph/solvate definition
- If claims recite a specific salt form, a generic using another salt may avoid literal infringement.
- Dosage range and schedule
- If claims specify frequency or dose ranges, label-aligned regimen changes can reduce infringement.
- Route and dosing form
- Injectable vs oral, or capsule vs tablet constraints, can move claims out of reach if the generic’s product differs.
- Formulation constraints
- Claims that recite excipient composition or concentration ranges are often a stronger barrier than composition-only claims.
- Combination and patient subset
- When method claims define a specific therapeutic group, avoiding that subset can reduce risk.
Strategic implication: For freedom-to-operate, generics should focus claim parsing on these dimensions first, because they typically determine whether design-arounds are available without changing the therapeutic equivalence in regulatory terms.
How does JP7574204 interact with other Japan patents on the same drug?
In a layered originator landscape, later patents often aim to:
- extend enforceability by shifting from broad active-ingredient claims to specific improvements (salt/formulation/regimen)
- add a second line of defense if earlier claims are invalidated or non-infringeable against a particular generic
So JP7574204’s business function usually falls into one of two roles:
- Defensive broadening: claims remain broad but are positioned as improvements that still read on the core marketed product
- Narrow re-targeting: claims are narrower but more enforceable against likely generic embodiments
What this means for enforcement timing
- If JP7574204 has remaining term and is still active, it can delay generic launch even if earlier patents have expired.
- If the claims are narrow and already avoided by market entrants (same ingredient but different form/regimen), JP7574204’s practical enforcement leverage is reduced to niche products.
What is the practical patent strategy signal for investors and R&D teams?
JP7574204’s portfolio value is determined less by the label of the patent and more by:
- how many commercially relevant product embodiments it covers
- how many generic competitors must redesign (form, regimen, or formulation) to avoid infringement
- whether it blocks the most likely entry route for ANDA-style or Japanese generic pathways that rely on regulatory equivalence
Actionable landscape signals:
- A patent set with broad composition + method claims tends to create sustained blocking power.
- A patent set that is composition-limited to a specific form tends to create “sparse blocking,” where only generics matching the exact form are at risk.
- A patent set that includes regimen and patient-subset constraints tends to create “label leverage,” where the originator can influence generic labeling to reduce infringement risk.
Key Takeaways
- JP7574204 sits as a Japan publication in a drug patent family where enforceability is typically concentrated in composition and/or method-of-treatment claim boundaries.
- The biggest FTO determinants for JP7574204 in Japan are usually active ingredient form (salt/polymorph/solvate), dosing regimen constraints, route/dosage form, and formulation parameters.
- In the Japan landscape, later publications like JP7574204 commonly function as layered protection that blocks generic entry even after earlier claims weaken, unless competitors already design around the specific form/regimen/formulation constraints.
- For investment and R&D planning, JP7574204 is best evaluated through the number of commercially relevant embodiments it covers and the availability of design-around routes that remain regulatory-viable in Japan.
FAQs
1) Is JP7574204 more likely to block generics through product claims or method claims in Japan?
In Japan, drugs patents that include enforceable “same product” definitions usually create the most direct barrier. The practical blocker is typically the composition/form claim set because it maps directly onto manufacturing and import of an infringing product.
2) What design-around choices most often reduce infringement risk for JP7574204-type patents?
The highest-yield levers are changing the active ingredient form (salt/polymorph), adjusting dose regimen and frequency to fall outside claimed ranges, and altering dosage form or formulation composition where claims specify formulation parameters.
3) How does claim wording around salt/polymorph affect generic freedom to operate?
When claims require a specific salt/polymorph/solvate, generics can sometimes avoid literal infringement by switching to a different form. If claims are broader or cover “selected forms,” the avoidance surface shrinks.
4) What does a layered Japan landscape imply for originators?
It implies that even if one claim set narrows or expires, later improvements can extend market exclusivity. The originator’s enforcement durability depends on whether later patents still read on market-generic product embodiments.
5) How should investors interpret JP7574204’s value versus earlier family members?
Treat it as an increment in enforceability only if it covers distinct, commercially relevant embodiments (a particular form, regimen, or formulation) that are not already avoided by competitor product designs.
References
[1] Japan Patent Office. JP7574204 (publication record). (APA citation format based on JPO bibliographic entry).
